Grace Therapeutics Inc 2025年度报告

FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended March 31, 2026 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from Commission file number: 001-35776 Grace Therapeutics, Inc. (Exact name of registrant as specified in its charter) State of Delaware98-1359336(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number) 103 Carnegie Center Suite 300Princeton, New Jersey 08540(Address of principal executive offices, including zip code) 609-322-1602(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).Yes☐No☒ The aggregate market value of the voting and non-voting shares of common stock held by non-affiliates of the registrant, based on theclosing sale price of the registrant’s common stock on September 30, 2025, the last business day of its most recently completed secondfiscal quarter, as reported on the Nasdaq Stock Market, was $35,051,405. The number of outstanding shares of common stock of the registrant, par value $0.0001 per share, as of June 15, 2026, was16,274,026. DOCUMENTS INCORPORATED BY REFERENCE Certain portions of the registrant’s definitive proxy statement for its 2026 annual meeting of stockholders, which the registrant intendsto file pursuant to Regulation 14A with the Securities and Exchange Commission no later than 120 days after the end of the registrant’sfiscal year to which this Annual Report on Form 10-K relates, are incorporated by reference into Part III of this Annual Report onForm 10-K. GRACE THERAPEUTICS, INC.(Formerly ACASTI PHARMA INC.) FORM 10-KFor the Fiscal Year Ended March 31, 2026Table of Contents PART IItem 1.Business7Item 1A.Risk Factors34Item 1B.Unresolved Staff Comments58Item 1C.Cybersecurity58Item 2.Properties59Item 3.Legal Proceedings59Item 4.Mine Safety Disclosures59PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities60Item 6.[Reserved]60Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operation61Item 7A.Quantitative and Qualitative Disclosures About Market Risk69Item 8.Financial Statements and Supplementary Data69Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure69Item 9A